(Q38025722)

27 August 2017

1 reference

title

The Crookshank lecture: biological response modifiers in the treatment of cancer (English)

1 reference

27 August 2017

Guillou PJ

1

1 reference

27 August 2017

language of work or name

1 reference

1 November 1990

1 reference

27 August 2017

1 reference

27 August 2017

volume

2

1 reference

27 August 2017

issue

6

1 reference

27 August 2017

page(s)

347-353

1 reference

Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980999-9

7 January 2021

Tumor necrosis factor: still a promising agent

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980999-9

7 January 2021

Inhibition of lymphokine-activated killer cell generation by cultured tumor cell lines in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980999-9

7 January 2021

Suppression of the generation of lymphokine-activated killer (LAK) cells by serum-free supernatants of in vitro maintained tumour cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980999-9

7 January 2021

A phase-II trial of recombinant interleukin-2 and 5-FU chemotherapy in patients with metastatic colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980999-9

7 January 2021

Recent advances in cellular immunology: implications for immunity to cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980999-9

7 January 2021

Recombinant interleukin-2 directly augments the cytotoxicity of human monocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980999-9

7 January 2021

Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980999-9

7 January 2021

Lymphokine activated killer (LAK) cells in patients with gastrointestinal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980999-9

7 January 2021

Decreased interleukin-2 production in patients with gastrointestinal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980999-9

7 January 2021

Paradoxical effects of 5-FU/folinic acid on lymphokine-activated killer (LAK) cell induction in patients with colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980999-9

7 January 2021

Alpha interferon for induction of remission in hairy-cell leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980999-9

7 January 2021

Class 1 (unique) tumor antigens of human melanoma. Identification of a 90,000 dalton cell surface glycoprotein by autologous antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980999-9

7 January 2021

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980999-9

7 January 2021

Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980999-9

7 January 2021

Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980999-9

7 January 2021

Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980999-9

7 January 2021

Lymphokine gene therapy for cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980999-9

7 January 2021

Effects of low dose perioperative interferon on the surgically induced suppression of antitumour immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980999-9

7 January 2021

Tumour necrosis factor in man: clinical and biological observations

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980999-9

7 January 2021

Alternating recombinant human interleukin-2 and dacarbazine in advanced melanoma. A multicentric phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980999-9

7 January 2021

Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980999-9

7 January 2021

Phase II study of alpha interferon on renal cell carcinoma. Summary of three collaborative trials

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980999-9

7 January 2021

Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980999-9

7 January 2021

10.1016/S0936-6555(05)80999-9

Identifiers

DOI

1 reference

27 August 2017

1 reference